Companies: 10,795·Total market cap: $144.5T
Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

FATENASDAQHealthcare● Active
$1.99
+$0.08(+4.19%)
Market Cap$231952410
P/E Ratio—
52W High$2.88
52W Low$0.91
SEC Filings

Fate Therapeutics, Inc. (FATE) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001434316 · FATE · NASDAQ · as of Jun 9, 2026

Filing snapshot

828
Total Filings
8-K
Latest Form
2026-06-04
Most Recent
2013
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001434316 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001193125-26-073699
Primary Document
fate-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001434316 · Accession 0001193125-26-073699

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-13
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-04Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-04
View
10-QQuarterly Report
10-Q
2026-05-13
View
8-KCurrent Report
8-K
2026-05-13
View
ARSARS
ARS
2026-04-24
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-24
View
DEF 14AProxy Statement
DEF 14A
2026-04-24
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-04-22
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
10-KAnnual Report
10-K
2026-02-26
View
8-KCurrent Report
8-K
2026-02-26
View
10-QQuarterly Report
10-Q
2025-11-13
View
8-KCurrent Report
8-K
2025-11-13
View
8-KCurrent Report
8-K
2025-10-27
View
3Initial Statement of Beneficial Ownership
3
2025-10-21
View
S-8Employee Stock Plan Registration
S-8
2025-10-20
View
Showing 1–15 of 446 filingsForm 4 / 144 hidden· 828 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001434316  |  Exchange: NASDAQ · Healthcare

Fate Therapeutics, Inc. (NASDAQ: FATE) has submitted 828 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2013. As a Healthcare sector company with CIK 0001434316, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Fate Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Fate Therapeutics, Inc. 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical FATE 10-K annual reports are available from 2008 through 2026.

Investors researching Fate Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
PRLD SEC Filings →ALEC SEC Filings →NKTX SEC Filings →MOLN SEC Filings →ABOS SEC Filings →CRBP SEC Filings →PEPG SEC Filings →VOR SEC Filings →
→ FATE Financials→ FATE Earnings→ FATE Insider Trades

Frequently Asked Questions

FATE SEC Filings · 8 questions

Fate Therapeutics, Inc. (FATE) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 828 filings and access original documents at no cost. Fate Therapeutics, Inc.'s CIK is 0001434316.

FATE SEC filingsFate Therapeutics, Inc. SEC documentsfind FATE 10-K